2023年CSCO头颈部肿瘤专场亮点更新药物汇总

On April 21-22, 2023, the CSCO Guidelines Conference was held in Guangzhou. At this conference, the "Chinese Society of Clinical Oncology (CSCO) Head and Neck Cancer Diagnosis and Treatment Guidelines 2023 Edition" was released. This article summarizes the key drugs updated at the conference. Please follow the editor to learn about it~

Head and neck tumors

Head and neck tumors generally refer to all malignant tumors from the base of the skull to the clavicle and in front of the cervical spine, except for the skull, cervical spine and eyes. The more common ones include nasopharyngeal cancer, laryngeal cancer, thyroid cancer, lip cancer, etc. The clinical symptoms of patients with head and neck tumors vary depending on the location of the tumor. Some patients may present with difficulty breathing, pain in swallowing, local swelling, coughing and hemoptysis, etc.

(Thyroid cancer pictures are from Baidu Encyclopedia, and will be deleted if there is any infringement)

Summary of updated drugs at the 2023 CSCO Head and Neck Cancer Special Session

The conference mainly adjusted the following drugs: newly added tislelizumab + gemcitabine + cisplatin (category 1A)c, toripalimab (category 2A)f, and camrelizumab (category 2A)f were upgraded to level I recommendations, while the level III recommendation added pembrolizumab + cetuximab (category 2A) b, nivolumab + cetuximab (category 2A] b, as shown in the figure.

This article summarizes the key drugs updated at the conference. The drug details are as follows:

1.

Tislelizumab injection can be used for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. On June 10, 2022, China's National Medical Products Administration (NMPA) approved BeiGene's anti-PD-1 antibody drug tislelizumab (tislelizumab injection) in combination with chemotherapy for the first-line treatment of patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). This is the ninth domestically approved indication for tislelizin and the PD-1 drug with the most approved indications in China.

2.

Toripalimab can be used as first-line treatment for nasopharyngeal carcinoma. On June 7, 2021, Professor Xu Ruihua, Director and Dean of the Sun Yat-sen University Cancer Prevention and Treatment Center, was invited to give a report at the plenary session of the American Society of Clinical Oncology (ASCO) annual meeting, a grand event in the global oncology field. The theme of the report was "JUPITER-02: A Comparative Tripp Randomized, double-blind, phase III clinical study of rimab or placebo combined with gemcitabine and cisplatin in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma" introduced the results of the JUPITER-02 study, which is the first Chinese innovative drug research to be selected for the plenary session in the official records of the ASCO annual meeting.

3.

Cetuximab is a targeted tumor therapy drug that specifically binds to the EGF (epidermal growth factor) receptor expressed on the surface of normal cells and various cancer cells, and competitively blocks EGF and other ligands. It is mainly used clinically to treat squamous cell carcinoma of the head and neck. It can slow down the progression of tumors and prolong the survival of patients. Whether used as a single agent or in combination with radiotherapy and chemotherapy, the drug can exert excellent anti-tumor activity in malignant tumors with positive EGFR expression, and can significantly improve the effects of radiotherapy and chemotherapy.